Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 78

Sort by

Sort Order Select

Journal Articles

Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 114.

https://doi.org/10.1182/blood-2024-198883

Published: 2024

Journal Articles

Treatment with 5-Azacytidine in High Risk MDS, CMML and AML: A Single Center Analysis with Regard to Days in Hospital and Days in Outpatient Clinic

Corinna Strupp, Annika Kasprzak, Andrea Kündgen, Fabian Czerwensky, Sascha Dietrich, Ulrich Germing

Blood (2024) 144 (Supplement 1): 7636.

https://doi.org/10.1182/blood-2024-205650

Published: 2024

Journal Articles

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Blood (2024) 144 (Supplement 1): 4407.

https://doi.org/10.1182/blood-2024-197897

Published: 2024

Journal Articles

Day 30 Mortality in Patients with AML: A Single Center Analysis Based on 1036 Patients

Alena Dalgic, Norbert Gattermann, Ulrich Germing, Sascha Dietrich, Felicitas Schulz, Guido Kobbe, Kathrin Nachtkamp, Sr., Paul Jäger

Blood (2024) 144 (Supplement 1): 1479.

https://doi.org/10.1182/blood-2024-205227

Published: 2024

Journal Articles

Immune Cell Infiltration Impacts Chemotherapy Efficacy in B-NHL

Peter-Martin Bruch, Christina Schniederjohann, Harald Voehringer, Matthias Meyer-Bender, Sarah Koziel, Lisa-Maria Held, Erin Kim Chung, Hilka Rauert-Wunderlich, Marita Ziepert, Norbert Gattermann, Gerhard Held, German Ott, Andreas Rosenwald, Wolfgang Huber, Sascha Dietrich

Blood (2024) 144 (Supplement 1): 4383.

https://doi.org/10.1182/blood-2024-209562

Published: 2024

Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Blood blood.2024025454.

https://doi.org/10.1182/blood.2024025454

Published: 2024

Includes: Supplemental data

Journal Articles

CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models

Berit J. Brinkmann, Alessia Floerchinger, Christina Schniederjohann, Tobias Roider, Mariana Coelho, Norman Mack, Peter-Martin Bruch, Nora Liebers, Sarah Dötsch, Dirk H. Busch, Michael Schmitt, Frank Neumann, Philipp M. Roessner, Martina Seiffert, Sascha Dietrich

Blood (2024) 144 (7): 784–789.

https://doi.org/10.1182/blood.2023022682

Published: 2024

Includes: Supplemental data

Journal Articles

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Blood (2024) 144 (5): 510–524.

https://doi.org/10.1182/blood.2023021990

Published: 2024

Includes: Supplemental data

Journal Articles

Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm

Camille Laurent, Sascha Dietrich, Karin Tarte

Blood (2024) 143 (12): 1080–1090.

https://doi.org/10.1182/blood.2023021000

Published: 2024

Journal Articles

A Propensity Score-Matched Analysis on the Outcomes of Brexucabtagene Autoleucel from Zuma-2 Study and Allogeneic Stem Cell Transplantation from the EBMT Database in Relapsed and Refractory Post-Btki Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3494.

https://doi.org/10.1182/blood-2023-174368

Published: 2023

Journal Articles

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 174.

https://doi.org/10.1182/blood-2023-189835

Published: 2023

Journal Articles

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Blood (2023) 142 (Supplement 1): 1771.

https://doi.org/10.1182/blood-2023-185992

Published: 2023

Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Blood (2023) 142 (Supplement 1): 603.

https://doi.org/10.1182/blood-2023-173692

Published: 2023

Journal Articles

Feasibility and Safety of the First-in-Human Chemotherapy-Light Combination of Rituximab, Polatuzumab Vedotin and Glofitamab in Previously Untreated Aggressive B-Cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOP - R-Pola-Glo/Ikf-t062, a Study of the Austrian Group for Medical Tumor Therapy (AGMT-NHL-16) and the German Lymphoma Alliance (GLA2022-10)

Thomas Melchardt, Rebecca I Wurm-Kuczera, Bettina Altmann, Petra Pichler, Manuel Orlinger, Michael Panny, Luisa Wohn, Andreas Rosenwald, Dirk Hellwig, Sascha Dietrich, Bertram Glass, Georg Lenz, Ulrich Keller, Marita Ziepert, Richard Greil, Bjoern Chapuy

Blood (2023) 142 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2023-188854

Published: 2023

Journal Articles

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

Julia M. Unglaub, Berit Brinkmann, Qian Chen, David Sedloev, Peter-Martin Bruch, Carolin Kolb, Volker Eckstein, Yi Liu, Anita Schmitt, Simon Raffel, Michael Schmitt, Carsten Müller-Tidow, Junyan Lu, Sascha Dietrich, Tim Sauer

Blood (2023) 142 (Supplement 1): 5969.

https://doi.org/10.1182/blood-2023-181251

Published: 2023

Journal Articles

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

Robert J. Kreitman, Philippe Moreau, Farhad Ravandi, Martin Hutchings, Anas Gazzah, Anne-Sophie Michallet, Zev A. Wainberg, Alexander Stein, Sascha Dietrich, Maja J. A. de Jonge, Wolfgang Willenbacher, Jacques De Grève, Evgeny Arons, Palanichamy Ilankumaran, Paul Burgess, Eduard Gasal, Vivek Subbiah

Blood (2023) 141 (9): 996–1006.

https://doi.org/10.1182/blood.2021013658

Published: 2023

Includes: Supplemental data

Journal Articles

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Blood (2022) 140 (24): 2594–2610.

https://doi.org/10.1182/blood.2021014241

Published: 2022

Includes: Supplemental data

Journal Articles

Single-Cell Omics Analyses Identify the TIM-3 Ligand Galectin-9 As Novel Immunotherapy Target for Chronic Lymphocytic Leukemia

Laura Llaó Cid, John KL Wong, Marina Wierz, Yashna Paul, Tobias Roider, Iria Fernandez Botana, Susanne Gonder, Alessia Floerchinger, Dolors Colomer, Elías Campo, Sascha Dietrich, Peter Lichter, Marc Zapatka, Etienne Moussay, Jérôme Paggetti, Martina Seiffert

Blood (2022) 140 (Supplement 1): 1805–1806.

https://doi.org/10.1182/blood-2022-167183

Published: 2022

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Huang Huang, Juliana Min, Elicia Penuel, L. Elizabeth Budde

Blood (2022) 140 (Supplement 1): 1467–1470.

https://doi.org/10.1182/blood-2022-157691

Published: 2022

Journal Articles

Single-Cell Multi-Omic and Spatial Analysis of Nodal B Cell Non-Hodgkin Lymphomas Reveals Plasticity in B Cell Maturation As a Driver of Intratumor Heterogeneity

Donnacha Fitzgerald, Tobias Roider, Marc-A. Baertsch, Harald Vöhringer, Mareike Knoll, Bettina Budeus, Artur Kibler, Anna Mathioudaki, Léandra Caillé, Linsha Li, Johannes Mammen, Marc Seifert, Wolfgang Huber, Sascha Dietrich

Blood (2022) 140 (Supplement 1): 752–753.

https://doi.org/10.1182/blood-2022-156210

Published: 2022

NARROW

Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Treatment with 5-Azacytidine in High Risk MDS, CMML and AML: A Single Center Analysis with Regard to Days in Hospital and Days in Outpatient Clinic

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Day 30 Mortality in Patients with AML: A Single Center Analysis Based on 1036 Patients

Immune Cell Infiltration Impacts Chemotherapy Efficacy in B-NHL

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm

A Propensity Score-Matched Analysis on the Outcomes of Brexucabtagene Autoleucel from Zuma-2 Study and Allogeneic Stem Cell Transplantation from the EBMT Database in Relapsed and Refractory Post-Btki Mantle Cell Lymphoma

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Single-Cell Omics Analyses Identify the TIM-3 Ligand Galectin-9 As Novel Immunotherapy Target for Chronic Lymphocytic Leukemia

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Single-Cell Multi-Omic and Spatial Analysis of Nodal B Cell Non-Hodgkin Lymphomas Reveals Plasticity in B Cell Maturation As a Driver of Intratumor Heterogeneity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only